您搜索了: karbamazepinom (斯洛文尼亚语 - 英语)

karbamazepinom ali
lopinavir:

karbamazepinom in valproatom)
investigations

sočasna uporaba s karbamazepinom je kontraindicirana.
co-administration with carbamazepine is contraindicated.

diplopija (če se uporabi v kombinaciji s karbamazepinom)
diplopia (when used in combination with carbamazepine)

med sočasno uporabo aripiprazola s karbamazepinom je treba odmerek aripiprazola podvojiti.
aripiprazole dose should be doubled when concomitant administration of aripiprazole occurs with carbamazepine.

med sočasno uporabo zdravila abilify s karbamazepinom je treba odmerek zdravila abilify podvojiti.
abilify dose should be doubled when concomitant administration of abilify occurs with carbamazepine.

med gabapentinom in fenobarbitalom, fenitoinom, valproinsko kislino ali karbamazepinom niso ugotovili medsebojnega delovanja.
no interaction between gabapentin and phenobarbital, phenytoin, valproic acid, or carbamazepine has been observed.

osebe so bile randomizirane v skupini s karbamazepinom in zonisamidom in so zdravilo glede na odziv prejemale do 24 mesecev.
subjects were randomised to carbamazepine and zonisamide received treatment for a duration of up to 24 months depending on response.

uporabi v kombinaciji s karbamazepinom) navzea, bruhanje bolezni prebavil fotosenzitivnost, bolezni kože in podkožja
nervous system disorders eye disorders

glede na odziv posameznega bolnika bo morda treba odmerek eslikarbazepinacetata povečati, kadar se ga uporablja sočasno z karbamazepinom.
based on individual response, the dose of eslicarbazepine acetate may need to be increased if used concomitantly with carbamazepine.

delež bolnikov, ki so se zdravili s karbamazepinom in so bili šest mesecev brez napadov, je bil 74,7 %.
the percentage of patients on carbamazepine who were seizure-free for six months was 74.7%.

67 karbamazepinom, kar je pripeljalo do vrednosti risperidona in 9- hidroksi- risperidona, ki so nižje od terapevtskih.
a possible explanation for the failure of this study was induction of risperidone and 9-hydroxy-risperidone clearance by carbamazepine, leading to subtherapeutic levels of risperidone and 9-hydroxy-risperidone.

klinično pomembnega učinka med uporabo z drugimi induktorji (npr. karbamazepinom, fenitoinom, fenobarbitalom) ni pričakovati.
a clinically relevant effect with other inducers (e.g. carbamazepine, phenytoin, phenobarbital) is not expected.

19 veliki meri, povzročeno s 35% zvišanjem ledvičnega očistka paliperidona, verjetno zaradi indukcije ledvičnega p- gp s karbamazepinom.
this decrease is caused, to a substantial degree, by a 35% increase in renal clearance of paliperidone likely as a result of induction of renal p-gp by carbamazepine.

ni dovolj podatkov, ki bi podprli priporočilo za presejalni pregled za hla-a*3101 pred začetkom zdravljenja s karbamazepinom ali sorodnimi kemijskimi spojinami.
there are insufficient data supporting a recommendation for hla-a*3101 screening before starting carbamazepine or chemically-related compounds treatment.

v nekliničnih poskusih je lakozamid v kombinaciji z levetiracetamom, karbamazepinom, fenitoinom, valproatom, lamotriginom, topiramatom ali gabapentinom pokazal sinergistične ali aditivne antikonvulzivne učinke.
in non-clinical experiments lacosamide in combination with levetiracetam, carbamazepine, phenytoin, valproate, lamotrigine, topiramate or gabapentin showed synergistic or additive anticonvulsant effects.

to znižanje je, v veliki meri, povzročeno s 35 % zvišanjem ledvičnega očistka paliperidona, verjetno zaradi indukcije ledvičnega p-gp s karbamazepinom.
this decrease is caused, to a substantial degree, by a 35% increase in renal clearance of paliperidone likely as a result of induction of renal p-gp by carbamazepine.

pričakovati je, da se izpostavljenost lesinuradu zmanjša, če je uporabljen sočasno z induktorji cyp2c9 (npr. s karbamazepinom, ki je zmeren induktor cyp2c9).
lesinurad exposure is expected to decrease when it is co-administered with inducers of cyp2c9 (e.g. carbamazepine, a moderate cyp2c9 inducer).

zato se je treba sočasni uporabi tolvaptana z močnimi induktorji cyp3a (npr. rifampicinom, rifabutinom, rifapentinom, fenitoinom, karbamazepinom in šentjanževko) izogniti.
therefore, concomitant administration of tolvaptan with potent cyp3a inducers (e.g., rifampicin, rifabutin, rifapentin, phenytoin, carbamazepine, and st. john’s wort) is to be avoided.

uporaba sutenta z induktorji družine cyp3a4 (npr. deksametazonom, fenitoinom, karbamazepinom, fenobarbitalom ali hypericum perforatum, znano tudi kot šentjanževka) lahko zniža koncentracijo sunitiniba.
john’ s wort) may decrease sunitinib concentrations.